Tid
1.1.2025–31.12.2028
Projektägare
Åbo Akademi
Samarbetsparter
Finansiär
Budget
7 767 276 euro
Åbo Akademis del av budgeten
2 388 109 euro (31%)
The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson’s, Alzheimer’s, schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and inefficient drug development for these diseases by establishing advanced non-animal alternatives for testing and predicting nanoparticle (NP)-based drug delivery across the human BBB. This approach aligns with EU and global initiatives to reduce animal testing and advance human-based biomedical research models.
Kontakta oss
Cecilia Sahlgren (Ansvarig forskare)
Professor
i cellbiologi
Biokemi och cellbiologi
Tfn +358 503009680
Jessica Rosenholm (Ansvarig forskare)
Professor
i farmaci företrädesvis läkemedelsutveckling
Farmaci
Tfn +358 504605886
Hongbo Zhang (Ansvarig forskare)
Professor
in Functional Biomaterials in Pharmacy
Farmaci
Tfn +358 503061491
Sebastien Lafond (Ansvarig forskare)
Professor
in Software Engineering
Informationsteknologi
Tfn +358 405464024